No long-term data are available on the efficacy of glargine insulin in comparison with
continuous sc insulin infusion (CSII) in children and adolescents affected by Type 1 diabetes …

Objective The advantages of continuous subcutaneous insulin infusion (CSII) or insulin
glargine have been demonstrated both in adult and paediatric diabetic patients; however, as …

Background: Continuous subcutaneous insulin infusion (CSII) is an effective method of
insulin substitution with increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in …

Objective. The aim of this study was to evaluate the metabolic effects of continuous
subcutaneous insulin infusion (CSII) with flexible multiple daily insulin (FMDI; premeal …

OBJECTIVE—The efficacy of the insulin analogs now available for multiple daily injection
(MDI) and continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes has …

Background: Studies comparing continuous subcutaneous insulin infusion (CSII) and
glargine in pediatric patients are scarce and cover only 1 year follow up. Although short-term …

Continuous subcutaneous insulin infusion (CSII) with a portable insulin pump has been
used for several years in the treatment of adult patients with diabetes mellitus (DM). This …

Aims To determine the safety and effectiveness of continuous subcutaneous insulin infusion
(CSII) in attaining long‐term glycaemic control in paediatric patients with Type 1 diabetes …

OBJECTIVES: To compare long-acting insulin glargine (Lantus) with intermediate-acting
insulin (neutral protamine Hagedorn [NPH]/Lente) when used as the basal component of a …

Objective Guidelines for insulin dosing, including the insulin to carbohydrate ratio (I/C),
insulin sensitivity factor (ISF), and basal/bolus ratio guidelines, have been well established …